Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BP1001 + Dasatinib in Ph+ CML, AML, and MDS
NCT02923986Phase 2Withdrawn
- Sponsor
- Bio-Path Holdings, Inc.
- Start
- Sep 2017
- Primary completion
- May 2020
- Modality
- Nanoparticles, Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of prexigebersen in chronic myeloid leukemia (CML), acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Bio-Path Holdings, Inc. Primary endpoints: Dose Limiting Toxicity at 240 days, Maximum Tolerated Dose at 240 days and 3 more. Planned start Sep 2017; status: withdrawn.
02
Drugs
prexigebersen
03
Conditions
chronic myeloid leukemia (CML)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02923986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02923986.